Status:
UNKNOWN
IPS Differentiated Cardiomyocytes Vein Transplantation for Chronic Heart Failure
Lead Sponsor:
Beijing University of Chinese Medicine
Collaborating Sponsors:
Dongzhimen Hospital, Beijing
Conditions:
Chronic Heart Failure
Eligibility:
All Genders
30-80 years
Phase:
PHASE2
PHASE3
Brief Summary
Based on the safety evaluation of primates, the best cell transplantation scheme was integrated. One patient with CHF caused by coronary heart disease, one patient with CHF caused by dilatation and on...
Eligibility Criteria
Inclusion
- It accords with the diagnostic standard of chronic heart failure.
- The etiological diagnosis accords with the corresponding diagnostic standard.
- The age is 30\~80 years old.
- Cardiac function classification is III- grade IV.
- Signed informed consent.
Exclusion
- Those who did not meet the diagnostic criteria and were included in the standard.
- Patients with severe dyspnea (such as COPD with pulmonary encephalopathy, upper gastrointestinal bleeding, etc.) accompanied by obvious hypoxemia and hemodynamic instability.
- Patients with severe primary diseases, such as liver and kidney diseases, hematological diseases, autoimmune diseases, malignant tumors, progressive diseases or diseases with poor prognosis, such as severe infection, severe water and electrolyte disorders, acid-base imbalance.
- Various infectious diseases.
- Participants in other clinical trials in the past two months.
Key Trial Info
Start Date :
December 31 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT03759405
Start Date
December 31 2022
End Date
December 31 2024
Last Update
July 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing University of Chinese Medicine
Beijing, Beijing Municipality, China, 100029